Trials / Completed
CompletedNCT02032095
The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Japan Blood Products Organization · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
It is intended to examine the safety and efficacy of desensitization therapy by GB-0998 (intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of pre-transplant desensitization. Patients with positive FCXM-T after performing twice double filtration plasmapheresis (DFPP) therapy will receive GB-0998 1g/kg/day for four days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GB-0998 |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2014-01-09
- Last updated
- 2016-02-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02032095. Inclusion in this directory is not an endorsement.